Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Sep;37(5):823-9.
doi: 10.1007/s10545-014-9686-7. Epub 2014 Mar 5.

Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series

Christina Lampe  1 , Ann-Kathrin Bosserhoff, Barbara K Burton, Roberto Giugliani, Carolina F de Souza, Camila Bittar, Nicole Muschol, Rebecca Olson, Nancy J Mendelsohn
Affiliations
Multicenter Study

Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series

Christina Lampe et al. J Inherit Metab Dis. 2014 Sep.

Abstract

Introduction: No published clinical trial data are available to inform the use of enzyme replacement therapy (ERT) in patients with the severe (neuropathic) phenotype of mucopolysaccharidosis II (MPS II). Current guidelines recommend ERT administered intravenously be used on a trial basis in this population.

Aims/methods: A retrospective chart review was conducted at five international centers for this case series of 22 patients with neuropathic MPS II who received intravenous idursulfase 0.5 mg/kg weekly for at least 2 consecutive years. We collected data about urinary glycosaminoglycan levels, adverse events, and the following somatic signs/symptoms: skeletal disease, joint range of motion, liver/spleen size, respiratory infections, cardiac disease, diarrhea, skin/hair texture, and hospitalizations.

Results: The age at diagnosis was 2 months to 5 years, and the age at idursulfase initiation was between 18 months and 21 years. One of 22 patients experienced improvements in seven somatic signs/symptoms; 17/22 experienced improvements in five to six somatic signs/symptoms; and 4/22 experienced improvements in four somatic signs/symptoms. None experienced fewer than four improvements. No new safety concerns arose. Infusion-related reactions were experienced by 4/22 patients but were successfully managed using accepted strategies.

Conclusions: Long-term treatment with idursulfase was associated with improvements in somatic manifestations in this case series of patients with neuropathic MPS II. The family and medical team should maintain open lines of communication to make treatment decisions that take into consideration the benefits and limitations of ERT in this population.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percent change in urinary glycosaminoglycan (uGAG) levels from baseline at last available test result for severe MPS II patients on long-term enzyme replacement therapy (ERT). *First available uGAG test result for patient 6 was after 7 months of ERT and for patient 14 was after 6 months of ERT. No baseline data are available. Here we report percent change between first available and last available uGAG test results
See this image and copyright information in PMC

References

    1. Bach G, Eisenberg F, Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A. 1973;70:2134–2138. doi: 10.1073/pnas.70.7.2134. - DOI - PMC - PubMed
    1. Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child. 1995;73:77–81. doi: 10.1136/adc.73.1.77. - DOI - PMC - PubMed
    1. Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM. Blood–brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24:1741–1749. doi: 10.1021/bc400319d. - DOI - PubMed
    1. Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr. 2012;171:631–639. doi: 10.1007/s00431-012-1703-y. - DOI - PMC - PubMed
    1. Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. J Pediatr. 2008;152:723–727. doi: 10.1016/j.jpeds.2007.10.015. - DOI - PubMed

Publication types

MeSH terms